Data highlights from EHA 2025
The latest new trial data presented at the 30th European Hematology Association (EHA) 2025 Congress.
Bispecific antibody for diffuse large B-cell lymphoma
Genmab shared new results from the Phase Ib/II EPCORE NHL-2 trial Arm 10 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE).
The drug is being investigated in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are eligible for autologous stem cell transplantation (ASCT).
Results demonstrated an overall response rate (ORR) of 87%, a complete response (CR) rate of 65% and a partial response (PR) of 23%. The majority of patients (65%) proceeded to ASCT.
At six months, an estimated 81% of responses were ongoing, 74% of patients were progression free, and 100% of patients were alive.
Bispecific antibody combination for multiple myeloma
Janssen-Cilag announced results from the Phase II RedirecTT-1 study evaluating the investigational combination of Talvey (talquetamab) Tecvayli (teclistamab).
The results show a high overall response rate (ORR) with durability in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) who have true extramedullary disease (EMD).
EMD represents an aggressive form of multiple myeloma and occurs when myeloma cells spread and form tumours (plasmacytomas) elsewhere in the body, such as in soft tissues and organs.
The study enrolled 90 patients with TCE RRMM with true EMD. The investigational combination of talquetamab and teclistamab led to a high ORR of 78.9%, with more than half of patients achieving complete response or better.
Among responders, 66.2% remained in response at the data cutoff, with a median follow-up of 13.4 months, signalling deep and durable responses. Treatment with the combination resulted in 61% of patients progression-free and alive at one year.
CAR-T for non-Hodgkin’s lymphoma
Galapagos presented new data from the ongoing ATALANTA-1 Phase I/II study of its investigational CD19 CAR T-cell therapy, GLPG5101, in relapsed/refractory non-Hodgkin’s lymphoma (NHL).
With a rapid vein-to-vein time enabled by Galapagos’ decentralised manufacturing platform, 95% of patients treated in the study received fresh, non-cryopreserved GLPG5101, without the need for cytotoxic bridging therapy.
GLPG5101 showed an encouraging safety profile in the context of robust CAR T-cell peak expansion and durable persistence, with the majority of Grade ≥ 3 treatment emergent adverse events being haematological.
Cases of CRS and ICANS were few and predominantly low-grade with only a single Grade 3 report of each. Dose-limiting toxicities were found in 8% of patients.
Durable CAR T-cell persistence was observed up to 21 months across tumour types, phases, and dose levels.
Microbiome treatment for acute Graft-vs-Host Disease
MaaT Pharma shared updated data for Xervyte (MaaT013) in treating acute Graft-versus-Host Disease (aGvHD) under the Early Access Program (EAP).
The dataset further supports the efficacy and safety profile of Xervyteg previously shown in the pivotal ARES trial and serves as supportive data within the Marketing Authorization Application (MAA) recently submitted to the European Medicines Agency (EMA).
aGvHD is a major cause of morbidity and mortality following allogeneic haematopoietic stem cell transplantation.
The patients treated in EAP previously failed one to six aGvHD systemic treatment lines and most had grade III or IV aGvHD.
The Gastrointestinal Overall Response Rate (GI-ORR) was 53% at D28, with Complete Response (CR) observed in 30% of patients; all-organ ORR was 50% with 26% CR.
The response was maintained at D56 indicating a long-term disease control with a GI-ORR of 47% and an ORR considering all organs of 46%.
OS in all patients was 55% at six months, 48% at 12 months, 44% at 24 months.
Median survival in all patients was 312 days. In responder patients, median survival was 834 days vs. 69 days in non-responders.
CAR-T for multiple myeloma
Arcellx announced new positive data from its pivotal Phase II iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM).
The ORR was 97%, with a complete response/stringent complete response (CR/sCR) rate of 68% and a very good partial response or higher (>VGPR) rate of 85%, per International Myeloma Working Group (IMWG) criteria as investigator-assessed.
Of those evaluable for minimal residual disease (MRD) testing at the time of the data cut, 93.3% achieved MRD negativity at a minimum of 10-5 sensitivity.
Six-month progression-free survival (PFS) and OS rates were 91.9% and 96.6%, respectively, and 12-month PFS and OS rates were 78.8% and 95.2%, respectively.
No delayed or non-immune effector cell-associated neurotoxicity syndrome (ICANS) neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel.
A kinase inhibitor for chronic myeloid leukaemia
Enliven Therapeutics revealed updated, positive data from the Phase I ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukaemia (CML).
ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with CML.
As of the cutoff date of 28 April 2025, the vast majority of patients (80%) remain on study with a median treatment duration of ~29 weeks.
Of the enrolled patients, 53 with typical BCR::ABL1 transcripts and without T315I mutations were evaluable for major molecular response (MMR) by 24 weeks.
- 25 of 53 (47%) evaluable patients were in MMR by 24 weeks, with 13 of 41 (32%) achieving and 12 of 12 (100%) maintaining MMR
- Of those resistant to their last TKI, 14 of 34 (41%) were in MMR by 24 weeks
- Of those previously treated with asciminib or ponatinib, 12 of 34 (35%) were in MMR by 24 weeks
- All patients who achieved or maintained MMR were still in MMR at the time of data cutoff
Cancer vaccine for multiple myeloma
Circio Holding presented interim data from the TG01 Phase I/II clinical trial in multiple myeloma at Oslo University Hospital (OUS).
The results show preliminary signals of clinical efficacy for TG01 vaccination and confirm an excellent safety profile, thus providing justification for continued clinical development for a major unmet medical need.
The trial was a collaboration between OUS and Circio to test TG01/QS-21 vaccination as a monotherapy in 20 KRAS or NRAS mutated multiple myeloma patients with remaining measurable disease after completion of standard of care treatment.
The aim was to assess whether T-cell responses to mutant RAS induced by TG01 can enhance and prolong the clinical benefit.
A tyrosine kinase inhibitor for acute lymphoblastic leukaemia
Ascentage Pharma announced results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918.
In multiple studies, the third-generation tyrosine kinase inhibitor (TKI) olverembatinib showed broad therapeutic potential in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL).
According to the results, olverembatinib demonstrated high complete remission (CR) and complete molecular response (CMR) rates, as well as favourable tolerability in the first-line treatment of newly diagnosed and relapsed/refractory Ph+ ALL, and specific subtypes of some haematologic malignancies (e.g., myeloid/lymphoid neoplasm with FGFR1 rearrangement).
In the olverembatinib + blinatumomab study, all patients achieved complete remission after one cycle, the 18-month overall survival rate was 100% and the 18-month event-free survival rate was 91.6%.
In the olverembatinib + VP regimen study, there was a 100% overall response rate, the two-year overall survival rate was 96.3% and the two-year PFS rate was 96%.
A preclinical study of the investigational EED inhibitor APG-5918 showed the potent anti-tumour activity of APG-5918 in T-cell lymphoma and support further clinical development of the agent.
A BTK inhibitor for chronic lymphocytic leukaemia
Janssen-Cilag announced new data from a matching-adjusted indirect comparison (MAIC) analysis assessing the efficacy of Imbruvica (ibrutinib) in combination with venetoclax (I+V) vs acalabrutinib in combination with venetoclax (A+V) as fixed-duration (FD) treatments for adults with previously untreated chronic lymphocytic leukaemia (CLL).
Comparative analyses between the trials suggested that I+V significantly reduced the risk of progression or death by 47% when compared to patients treated with A+V.
The results also suggested that patients treated with I+V were almost twice and 2.4 times more likely to achieve disease clearance, as measured by undetectable minimal residual disease (uMRD) three months after the end of treatment (EOT+3), from both peripheral blood (PB) and bone marrow (BM).
Long-term follow-up results from the Phase II CAPTIVATE study data were also presented, which demonstrated patients in the I+V FD cohort displayed a clinically meaningful PFS and OS vs. the MRD-guided cohort.
After a median follow-up of 68.9 months, the 5.5-year PFS and OS rates for all treated patients were 66% and 97%, respectively. Additionally, the 5.5-year PFS rate in patients who achieved uMRD in the PB at the EOT was 71%.
Furthermore, one-year PFS and OS rates from the start of retreatment (with single-agent ibrutinib or FD I+V) were both 100%, whilst two-year PFS and OS rates from the start of retreatment were 91% and 96%, respectively.
Diana Spencer, Senior Digital Content Editor, DDW
